Clinical Trials Using Plinabulin

Clinical trials are research studies that involve people. The clinical trials on this list are studying Plinabulin. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Nivolumab, Ipilimumab, and Plinabulin in Treating Patients with Recurrent Extensive Stage Small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of plinabulin when given together with nivolumab and ipilimumab and to see how well they work in treating patients with extensive stage small cell lung cancer that has come back. Plinabulin blocks tumor growth by targeting both new and existing blood vessels going to the tumor as well as killing tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving plinabulin with nivolumab and ipilimumab may work better in treating patients with extensive stage small cell lung cancer compared to standard chemotherapy.
    Location: 5 locations

  • Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

    To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. Secondary purposes of the study are: - To compare the neutropenia (incidence of Grade 4 neutropenia [absolute neutrophil count (ANC) < 0.5 × 10^9 / L]) on Day 8 (+ / - 1 day) of Cycle 1), DoR, neutrophil count on Day 8 (+ / - 1 day) of Cycle 1, incidence of docetaxel dose reduction and / or docetaxel dose withheld in Cycle 2 due to neutropenia in Cycle 1, QoL (EORTC QLQ-C30 [item 30, average overall quality of life over all observable weeks]), ORR, and PFS in patients with NSCLC treated in the DP Arm to patients treated in the D Arm as 2nd- or 3rd-line therapy for advanced or metastatic disease. - To compare the safety and adverse events profile of the DP Arm to D Arm. - To compare dose intensity of docetaxel (percent dose administered compared to dose assigned) between the 2 treatment arms. - To evaluate population pharmacokinetics in patients enrolled in China and rest of world (RoW).
    Location: 4 locations

  • Nivolumab in Combination with Plinabulin in Treating Patients with Metastatic Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of plinabulin when given with nivolumab in treating patients with non-small cell lung cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as plinabulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and plinabulin together may be a better treatment for patients with non-small cell lung cancer.
    Location: University of California San Diego, San Diego, California